(MEMPHIS, TENN. - February 9, 2015) St. Jude Children's Research Hospital investigators have discovered inherited genetic variations that are associated with rapid hearing loss in young cancer patients treated with the drug cisplatin. The research appears in the current online issue of the scientific journal Nature Genetics.
Cisplatin is one of the most widely used anti-cancer drugs and is a mainstay of treatment for children and adults with many types of brain and other solid tumors. But in some patients the drug causes debilitating side effects, including severe hearing loss. The risk factors involved are not completely understood. "Even for children receiving uniform therapy, there is substantial variability in their hearing damage after cisplatin treatment, and we suspect this has to do with differences in patients' genetic make-up," said co-corresponding author Jun J. Yang, Ph.D., an assistant member of the St. Jude Department of Pharmaceutical Sciences.
Researchers checked the DNA of 238 young brain tumor patients for more than 1.7 million common genetic variations. Variations in a gene named ACYP2 were associated with as much as a four-fold greater risk of cisplatin-related hearing loss. The screening is among the first to survey the genetic landscape for clues to help explain why the risk of cisplatin-related hearing loss varies so widely among patients. St. Jude is a leader in research to improve medication safety and effectiveness. Its research aims to understand how inherited genetic variations affect the way individuals metabolize and respond to drugs.
"This is an important first step in being able to pinpoint patients who are at higher risk of developing cisplatin toxicity and to learn how to better manage that risk," said co-corresponding author Clinton Stewart, Pharm.D., a member of the St. Jude Department of Pharmaceutical Sciences.
The association between the high-risk ACYP2 variants and cisplatin-related hearing loss was confirmed in a separate group of 68 young brain tumor patients. The link was independent of other risk factors for cisplatin-related hearing loss, including patient age and radiation therapy.
Twenty-four of the 306 patients in this study had at least one copy of the high-risk ACYP2 variant. All 24 patients had measurable hearing loss that occurred as early as weeks after beginning cisplatin therapy. Overall, however, the ACYP2 variant explained a relatively small proportion of hearing damage. Just 12.4 percent of the 194 patients in this study with cisplatin-related hearing loss carried the ACYP2 variant.
"This suggests that other genes also contribute to the risk of hearing loss and are yet to be identified," Yang said. "Further research is needed to understand how the ACYP2 variations modify the risk facing patients of cisplatin toxicity."
Such studies could potentially lead to new medications to protect high-risk patients from cisplatin-related toxicity or help identify candidates for intensive monitoring of their hearing. Early intervention could then be offered if problems are identified, Stewart said.
This study included patients enrolled in one of three clinical trials designed by St. Jude investigators for newly diagnosed pediatric brain tumors. The protocols involved similar treatment, including surgery to remove as much of the tumor as possible followed by radiation, which was modified based on patient age and other risk factors. The patients were scheduled to receive four rounds of cisplatin therapy. Patients' hearing was tested before treatment began, after radiation therapy, after each round of chemotherapy and then at regular standardized intervals. Analysis of the resulting data led to identification of ACYP2 and other variants.
"Our primary goal is to cure children with brain tumors, but we also have a duty to help patients survive with a high quality of life. Hearing loss can have a significant impact on a child's quality of life, language development and academic performance," said co-first author Giles Robinson, M.D., an assistant member of the St. Jude Department of Oncology. "There is no easy fix, but the more we know about the risk factors the better we will understand how to use cisplatin."
Heng Xu, M.D., formerly of St. Jude, is co-first author. The other authors are Jie Huang, Hui Zhang, Johnnie Bass, Alberto Broniscer, Tetsuji Yamashita, Tal Teitz, Jian Zuo, Arzu Onar-Thomas and Amar Gajjar, all of St. Jude; Joshua Yew-Suang Lim, formerly of St. Jude and now of National University of Singapore; Murali Chintagumpala, Baylor College of Medicine, Houston; Ute Bartels, Hospital for Sick Children, Toronto; Sri Gururangan, Duke University Medical Center, Durham, N.C.; Tim Hassall, Royal Children's Hospital, Parkville, Australia; Michael Fisher, Children's Hospital of Philadelphia; and Richard Cohn, University of New South Wales, Kensington, Australia.
The research was funded in part by grants (CA2176534, GM92666) from the National Institutes of Health and ALSAC.
St. Jude Media Relations Contacts
desk (901) 595-2295
cell (901) 297-9875
desk (901) 595-3061
cell (901) 297-9861
St. Jude Children's Research Hospital
St. Jude Children's Research Hospital is leading the way the world understands, treats and defeats childhood cancer and other life-threatening diseases. It is the only National Cancer Institute-designated Comprehensive Cancer Center devoted solely to children. Treatments developed at St. Jude have helped push the overall childhood cancer survival rate from 20 percent to 80 percent since the hospital opened more than 50 years ago. St. Jude is working to increase the overall survival rate for childhood cancer to 90 percent in the next decade. St. Jude freely shares the breakthroughs it makes, and every child saved at St. Jude means doctors and scientists worldwide can use that knowledge to save thousands more children. Families never receive a bill from St. Jude for treatment, travel, housing and food--because all a family should worry about is helping their child live. To learn more, visit stjude.org or follow St. Jude at @stjuderesearch.